Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The company's novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy; M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; and M230, a recombinant trivalent human IgG1 Fc multimer to block tissue damage mediated by immune complexes. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone617-491-9700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$138.88 million
Profitability
Miscellaneous
Employees279
OptionableOptionable
Momenta Pharmaceuticals (NASDAQ:MNTA) Frequently Asked Questions
What is Momenta Pharmaceuticals' stock symbol?
Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."
How were Momenta Pharmaceuticals' earnings last quarter?
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) announced its quarterly earnings data on Wednesday, November, 7th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.18. The biotechnology company earned $14.88 million during the quarter, compared to analyst estimates of $16.99 million. Momenta Pharmaceuticals had a negative net margin of 158.21% and a negative return on equity of 44.72%. The firm's revenue for the quarter was down 38.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.44) EPS. View Momenta Pharmaceuticals' Earnings History.
When is Momenta Pharmaceuticals' next earnings date?
What price target have analysts set for MNTA?
4 analysts have issued 12-month target prices for Momenta Pharmaceuticals' stock. Their forecasts range from $16.00 to $39.00. On average, they expect Momenta Pharmaceuticals' stock price to reach $30.00 in the next year. This suggests a possible upside of 155.1% from the stock's current price. View Analyst Price Targets for Momenta Pharmaceuticals.
What is the consensus analysts' recommendation for Momenta Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Momenta Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Momenta Pharmaceuticals.
What are Wall Street analysts saying about Momenta Pharmaceuticals stock?
Here are some recent quotes from research analysts about Momenta Pharmaceuticals stock:
- 1. Stifel Nicolaus analysts commented, "During our recent meeting with management, MNTA highlighted additional data from its Phase 1 studies for M281, its anti-FcRn candidate, (see page 3) which indicates its 30 mg/kg did not lower albumin outside the normal range. We believe this is important as some investors remain skeptical around M281’s safety profile after MNTA’s R&D day which indicated M281 not only lowered IgG but also was modestly lowering albumin. In our recent deep dive on M281’s safety controversies, we believed its potency would allow MNTA a good deal of flexibility to find a regimen offering low/no albumin lowering while maintaining a high level of IgG reduction." (1/8/2019)
- 2. According to Zacks Investment Research, "The completion of the strategic review has narrowed Momenta's focus on its biosimilar portfolio. Momenta will now advance only two late-stage biosimilar assets, M923, its wholly-owned proposed biosimilar to Humira and M710, its proposed biosimilar to Eylea. Momenta will also restructure its executive team and reduce its workforce by approximately 50%. The cost savings from the restructuring plan should enable the company to develop novel drug candidates for the treatment of rare, immune-mediated diseases. While the FDA approval of Glatopa 40 mg should relieve Momenta, competition has limited market share gains for the company as Mylan has already won the FDA’s approval for the same. Shares of the company have underperformed the industry in the past twelve months." (1/7/2019)
Has Momenta Pharmaceuticals been receiving favorable news coverage?
News articles about MNTA stock have been trending negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Momenta Pharmaceuticals earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the near term.
Who are some of Momenta Pharmaceuticals' key competitors?
Some companies that are related to Momenta Pharmaceuticals include Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Spark Therapeutics (ONCE), Regenxbio (RGNX), Editas Medicine (EDIT) and Autolus Therapeutics (AUTL).
Who are Momenta Pharmaceuticals' key executives?
Momenta Pharmaceuticals' management team includes the folowing people:
- Mr. Craig A. Wheeler, Pres, CEO & Exec. Director (Age 59)
- Dr. Ganesh Venkataraman Kaundinya, Co-Founder & Consultant (Age 52)
- Dr. Santiago Arroyo, Chief Medical Officer & Sr. VP of Devel.
- Mr. Bruce A. Leicher, Consultant (Age 63)
- Mr. Scott M. Storer, Consultant
Who are Momenta Pharmaceuticals' major shareholders?
Momenta Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Louisiana State Employees Retirement System (0.04%), State of Alaska Department of Revenue (0.03%) and Fox Run Management L.L.C. (0.01%). Company insiders that own Momenta Pharmaceuticals stock include Anthony M Manning, Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Jo Ann Beltramello, Santiago Arroyo, Scott M Storer and Young Kwon. View Institutional Ownership Trends for Momenta Pharmaceuticals.
Which institutional investors are buying Momenta Pharmaceuticals stock?
How do I buy shares of Momenta Pharmaceuticals?
Shares of MNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Momenta Pharmaceuticals' stock price today?
One share of MNTA stock can currently be purchased for approximately $11.76.
How big of a company is Momenta Pharmaceuticals?
Momenta Pharmaceuticals has a market capitalization of $1.09 billion and generates $138.88 million in revenue each year. The biotechnology company earns $-88,090,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Momenta Pharmaceuticals employs 279 workers across the globe.
What is Momenta Pharmaceuticals' official website?
How can I contact Momenta Pharmaceuticals?
Momenta Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-491-9700 or via email at [email protected]
MarketBeat Community Rating for Momenta Pharmaceuticals (NASDAQ MNTA)
MarketBeat's community ratings are surveys of what our community members think about Momenta Pharmaceuticals and other stocks. Vote "Outperform" if you believe MNTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
